Boston, MA 05/02/2014 (wallstreetpr) – Recently, Endo International PLC (NASDAQ:ENDP) has announced the results of the first quarter of this year. The results look positive, but the numbers have gone down as compared to the first quarter of the previous year. Endo International has announced the acquisition of two companies, namely, Sumavel DosePro and Grupo Farmaceutico Somar, as it progresses towards the path of becoming a global leader in healthcare.
Results announced
Endo International has reported total revenue of about $595 million, but this fell down as compared to the first quarter of the last year, which reported total revenues equal to $658 million. Endo International PLC (NASDAQ:ENDP) reported that it had suffered a net loss of $437 million in this quarter of the2014; while, in the first quarter of the previous year, it had earned a net income of 15 million. While the adjusted net income of Endo International is reported to be $134 million, which has increased by 9% as compared to the previous year’s $123 million.
The company also reported a loss per share equal to $3.41 while, in the first quarter of the year 2013, Endo International had reported an earning per share equal to $0.14. The adjusted diluted earning per share is reported to have fallen by 16% from $1.09 for Q1 of 2013 to $0.92 for Q1 of 2014.
The Chief Executive Officer of Endo International, namely, Rajiv De Silva said that the company has delivered a strong operative performance. The company has been executing against its strategic plans so as to transform Endo International into a leading global healthcare company. He also said that the main aim of Endo International PLC (NASDAQ:ENDP) is to build up a diversified portfolio, which should also be sustainable in order to provide products. This can be achieved only by coupling proper allocation of capital with strategic growth opportunities and investments in Endo International’s existing business.
